Key Highlights

  • BioLineRx shares settled up about 7%, near $2.78 to $2.80, versus Friday's $2.60.
  • Lead program GLIX1, an oral DNA-damage-response drug for glioblastoma, is in the second of five Phase 1 dose-escalation cohorts.
  • Cash stood at $13.1 million as of June 30, guided into the first half of 2027.
  • A $3.75 million registered direct and Warrant deal priced at $2.78 per ADS was set to close the same day.

BioLineRx Ltd. (NASDAQ: BLRX) shares settled up about 7% near $2.78 to $2.80 on Monday, versus Friday's $2.60, on a pipeline-and-runway update.

What Happened

Lead program GLIX1, an oral DNA-damage-response drug for glioblastoma, is in the second of five Phase 1 dose-escalation cohorts in a Phase 1/2a trial, with a third cohort due in September at sites including NYU Langone, Northwestern, and Moffitt. New preclinical work showed activity in TMZ-resistant glioblastoma xenografts and synergy with a PARP inhibitor in HR-proficient ovarian cancer.

Cash was $13.1 million at June 30, guided into the first half of 2027. A $3.75 million registered direct and warrant deal priced at $2.78 per ADS was set to close the same day. Q2 Royalty Revenue was about $0.3 million, with a net loss of about $4.3 million.

Market Reaction

The modest gain reflects a trial that is moving forward and cash that has been extended, with the new financing priced at Friday's closing level rather than at a discount, avoiding the kind of dilutive pressure that often weighs on similar announcements.

Outlook

The third dose-escalation cohort due in September represents the next disclosed milestone for GLIX1 in glioblastoma, a notoriously difficult tumor to treat.